For the qualitative determination of antibodies to filgrastim in human serum or plasma.
Contents of Kit
1.Microtiter Plate(s), 96 wells (12x8 strips)
2.Wash Buffer (20X)
3.Positive Control 1mg/mL
6.Detection Reagent (2000X)
8.TMB Stop Solution
Do not mix or substitute reagents with those from other lots.
Store kit components at 2-8°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes. It is produced by recombinant DNA technology. It serves to stimulate the production of granulocytes.
Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone hematopoietic cell proliferation and differentiation. Filgrastim is used to treat neutropenia, stimulating the bone marrow to increase production of neutrophils. The causes of neutropenia include chemotherapy and bone marrow transplantation.
In various clinical trials, filgrastim has been reported to generate an antibody response. Both binding and neutralizing antibodies against filgrastim have been reported. The formation of binding or neutralizing antibodies to a therapeutic agent may decrease the efficacy of these agents, leading to a loss of clinical response over time. In some cases, anti-drug antibodies may cause infusion reactions and serious anaphylactic reactions. Detection, measurement and characterization of anti-therapeutic antibodies are critical in understanding the safety, exposure and efficacy profile of the therapeutic agent.
The anti-Filgrastim ELISA kit is designed for the qualitative determination of antibodies to filgrastim in serum and plasma. Our ELISA-based kits combine a fast, user-friendly format with a sensitive and specific assay. The anti-Filgrastim ELISA kit can be used for monitoring anti-filgrastim antibodies during clinical research and offers the scientists a tool for understanding of the safety and efficacy of the filgrastim and its biosimilars.